|
DF/CHCC serves as the regional quaternary center for pediatric neuro-oncology. We oversee New England?s most active pediatric oncology clinical research program and can provide access to unique clinical trials for patients with newly diagnosed, relapsed or refractory brain tumors. We are New England?s Phase I Children?s Oncology Group referral center, a Pediatric Oncology Experimental Therapeutics Investigator Consortium (POETIC) member and a founding institution of the Pediatric Brain Tumor Consortium. We are also members of the Pediatric Blood and Marrow Transplant Consortium (PBMTC).
We have a dedicated pediatric neuro-oncology service for chemotherapy administration and other inpatient hospitalizations on a dedicated clinical Neurosciences floor at Children?s with specialized staff and nurses.
- Our outpatient clinic sees over 2000 visits per year.
- We care for an average of 125 new patients each year.
- We follow over 900 pediatric brain tumor survivors in our Outcomes Program.
We are skilled at improving current therapeutic approaches and outcomes of hard-to-treat pediatric brain tumors, such as atypical teratoid rhabdoid tumor (ATRT), low-grade astrocytoma (LGA), high-grade astrocytomas (HGA), diffuse intrinsic pontine glioma and medulloblastoma.
Graduates from the Pediatric Neuro-Oncology Fellowship program, which was established in 2001, have secured faculty positions at Dana-Farber/Children?s Hospital Cancer Care (Boston, MA), Royal Children?s Hospital (Melbourne, Australia), Children?s Hospital of Los Angeles (Los Angeles, CA), Hasbro Children?s Hospital (Providence, RI), and Memorial Sloan-Kettering Cancer Center (New York, NY), among others.
|